Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

Yang, Wenying; Zhu, Dalong; Gan, Shenglian; Dong, Xiaolin; Su, Jun-ping; Li, Wenhui; Jiang, Hongwei�; Zhao, Wenjuan; Yao, Minxiu; Song, Weihong; Lu, Yibing; Zhang, Xiuzhen; Li, Huifang; Wang, Guixia; Qiu, Wei; Yuan, Guoyue; Ma, Jianhua; Li, Wei; Li, Ziling; Wang, Xiaoyue; Zeng, Jiao’e; Yang, Zhou; Liu, Jingdong; Liang, Yongqian; Lu, Song; Zhang, Huili; Liu, Hui; Liu, Ping; Fan, Kuanlu; Jiang, Xiaozhen; Li, Yufeng; Su, Qing; Ning, Tao; Tan, Huiwen; An, Zhenmei; Jiang, Zhaoshun; Liu, Lijun; Zhou, Zunhai; Zhang, Qiu; Li, Xuefeng; Li, Xuefeng; Shan, Zhongyan; Xue, Yaoming; Mao, Hong; Shi, Lixin; Ye, Shandong; Zhang, Xiaomei; Sun, Jiao; Li, Ping; Yang, Tao; Lin, Jing‐Na; Lin, Jing‐Na; Zhang, Zhinong; Zhao, Ying; Li, Ruonan; Guo, Xiaohui; Yao, Qi; Lu, Weiping; Qu, Shen; Li, Hongmei; Tan, Liling; Wang, Wenbo; Yao, Yongli; Chen, Daoxiong; Li, Yulan; Gao, Jialin; Hu, Wen; Fei, Xiaoqiang; Wu, Tianfeng; Dong, Song; Jin, Wenlong; Li, Chenzhong; Zhao, Dong; Feng, Bo; Zhang, Yi; Zhang, Yi; Chen, Li; Kellis, M; Chen, Li

doi:10.1038/s41591-022-01803-5

Public

Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

Published in Nature Medicine • May 1, 2022

Authors:

Wenying Yang

Dalong Zhu

Shenglian Gan

Abstract

Metformin, the first-line therapy for type 2 diabetes (T2D), decreases hepatic glucose production and reduces fasting plasma glucose levels. Dorzagliatin, a dual-acting orally bioavailable glucokinase activator targeting both the pancreas and liver glucokinase, decreases postprandial glucose in pati...

Subject

Metformin

Medicine

Type 2 diabetes

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!